ClinicalTrials.gg
CompletedNCT02099656Updated Sep 6, 2017

A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma

A Phase 2 interventional study of Lebrikizumab and Placebo in Asthma, sponsored by Hoffmann-La Roche. Completed at 28 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-09-06.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing lebrikizumab in Asthma — none open to participants now, none under way, none of them phase 3. lebrikizumab · Asthma.

Enrollment
10th of 12
64 · median 224
Started
2014
with 2 others
Phase 2
7 of 12
none open now
Registered
10th of 12
by date
Lead sponsor
7 of 12
Hoffmann-La Roche

Among the 12 studies testing lebrikizumab in Asthma, this one is the 10th largest by enrollment, is one of 3 that started in 2014, is one of 7 in phase 2, and was the 10th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 12 studies testing lebrikizumab in Asthma is open now. The open studies under Asthma, anywhere →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing lebrikizumab in Asthma as a file.
02

Study summary

This Phase II, randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of lebrikizumab on airway eosinophilic inflammation in participants with uncontrolled asthma who are using inhaled corticosteroid (ICS) treatment and a second controller medication. Enrolled participants will undergo a 3-week screening period during which assessments, including a bronchoscopy procedure, will be made. Participants will subsequently be randomized to receive lebrikizumab or placebo by subcutaneous (SC) injection on Day 1, Day 8, Week 4, and Week 8. Participants will continue their standard of care therapy throughout the study. End of treatment assessments will be taken at Week 12. Total study period, including screening and follow-up, is expected to last 23 weeks.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asthma diagnosis for greater than or equal to (>/=) 12 months prior to Visit 1
  • Bronchodilator response demonstrated within the 12 months before Visit 1 or at Visit 1, 2, or 3 of screening
  • Pre-bronchodilator of 40 percent (%) - 80% predicted at both Visits 2 and 3
  • On ICS therapy at a total daily dose of 500-2000 mcg of fluticasone propionate dry powder inhaler (DPI) or equivalent for >/= 6 months prior to Visit 1, with no changes within 4 weeks prior to Visit 1, and no anticipated changes throughout the study
  • On an eligible second controller medication (long-acting Beta-agonist [LABA), leukotriene receptor antagonist [LTRA], long-acting muscarinic antagonists [LAMAs] or theophylline) for 6 months prior to Visit 1, with no changes within 4 weeks prior to Visit 1, and no anticipated changes throughout the study
  • Uncontrolled asthma at Visit 1 and/or 2 and at Visit 3
  • Chest X-ray or computed tomography (CT) scan within 12 months prior to Visit 1 or chest X-ray during the screening period (prior to Visit 3) that confirms the absence of other lung disease
  • Demonstrated adherence with controller medication during the screening period

Exclusion criteria

Exclusion Criteria:

  • Maintenance oral therapy, defined as daily alternate-day oral corticosteroid maintenance therapy within 3 months prior to Visit 1
  • Treatment with systemic corticosteroids within 4 weeks prior to Visit 1 or during the screening period for any reason, including an acute exacerbation event
  • Any infection requiring hospital, intravenous (IV) or intramuscular (IM) antibiotic treatment or any respiratory infection within 4 weeks prior to Visit 1 or during screening. Any infection requiring oral antibiotic treatment with 2 weeks prior to Visit 1 or during screening, or any parasitic infection within 6 months prior to Visit 1 or during screening
  • Active tuberculosis requiring treatment within 12 months prior to Visit 1
  • Known immunodeficiency, including, but not limited to, (HIV) infection
  • History of interstitial lung disease, (COPD), or other lung disease other than asthma
  • Known current or current evaluation for a potential malignancy
  • Unable to safely undergo elective flexible fiberoptic bronchoscopy
  • Clinically significant medical disease that is uncontrolled despite treatment, that is likely, in the opinion of the investigator, to impact the participant's ability to participate in the study, or to impact the study assessments
  • History of alcohol or drug abuse that would impair or risk the participant's full participation in the study, in the opinion of the investigator
  • Current smoker or history of smoking (greater than [>] 10 pack-years), or unwillingness to abstain from smoking for the duration of the study
  • Past and/or current use of any anti-interleukin (IL)-13 or anti-IL-4/IL-13 therapy, including lebrikizumab
  • Use of a licensed or monoclonal antibody other than anti-IL-13, or anti IL-4/IL-13, including, but not limited to, omalizumab, anti-IL-5, or anti-IL-17, within 6 months or 5 drug half-lives prior to Visit 1 (whichever is longer) or during screening
  • Use of a systemic immunomodulatory or therapy within 3 months or 5 drug half-lives prior to Visit 1 (whichever is longer) or during screening
  • Use of other investigational therapy within 4 weeks or 5 drug half-lives prior to Visit 1 (whichever is longer) or during screening
  • Initiation of or increase in allergen immunotherapy within 3 months prior to Visit 1 or during screening
  • >38 kilograms per square meter (kg/m\^2)
  • Body weight \<40 kilograms (kg)
  • History of bronchial thermoplasty
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Lebrikizumab

    Participants with uncontrolled asthma on ICS therapy (not specified in the protocol) and a second controller medication, will receive SC injection of lebrikizumab on Days 1 and 8, and on Weeks 4 and 8.

    Drug: Lebrikizumab · Drug: Inhaled corticposteroids (ICS) · Drug: Second Asthma Controller Medication

  • Placebo comparator
    Placebo

    Participants with uncontrolled asthma on ICS therapy (not specified in the protocol) and a second controller medication, will receive SC injection of lebrikizumab matching placebo on Days 1 and 8, and on Weeks 4 and 8.

    Drug: Placebo · Drug: Inhaled corticposteroids (ICS) · Drug: Second Asthma Controller Medication

Interventions

  • Lebrikizumab will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.

    Also known as: RO5490255

  • DrugPlacebo

    Lebrikizumab matching placebo will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.

  • DrugInhaled corticposteroids (ICS)

    Participants will continue their ICS controller therapy, as they are receiving prior to screening, throughout the study. Protocol does not specify any particular ICS.

  • DrugSecond Asthma Controller Medication

    Participants will continue their asthma controller therapy, as they are receiving prior to screening, throughout the study.

06

What researchers measure

Primary outcomes

  1. Relative Change From Baseline in the Number of Airway Submucosal Eosinophils per Surface Area of Basal Lamina (Cells per Square Millimeter [Cells/mm^2])

    Time frame: From Baseline to Week 12

Secondary outcomes

  1. Absolute Change From Baseline in Number of Airway Submucosal Eosinophils per Surface Area of Basal Lamina (Cells/mm^2)

    Time frame: From Baseline to Week 12

  2. Relative Change From Baseline in the Number of Airway Epithelial Eosinophils per Surface Area of Basal Lamina (Cells/mm^2)

    Time frame: From Baseline to Week 12

  3. Absolute Change From Baseline in Number of Airway Epithelial Eosinophils per Surface Area of Basal Lamina (Cells/mm^2)

    Time frame: From Baseline to Week 12

  4. Relative Change From Baseline in Number of Airway Submucosal Eosinophils per Volume of Submucosa (Cells per Cubic Millimeter [Cells/mm^3])

    Time frame: From Baseline to Week 12

  5. Absolute Change From Baseline in Number of Airway Submucosal Eosinophils per Volume of Submucosa (Cells/mm^3)

    Time frame: From Baseline to Week 12

  6. Relative Change From Baseline in Number of Airway Epithelial Eosinophils per Volume of Epithelium (Cells/mm^3)

    Time frame: From Baseline to Week 12

  7. Absolute Change From Baseline in Number of Airway Epithelial Eosinophils per Volume of Epithelium (Cells/mm^3)

    Time frame: Form Baseline to Week 12

  8. Change From Baseline in Blood Eosinophil Count

    Time frame: From Baseline to Week 12

  9. Change From Baseline in Immunoglobulin E (IgE) Levels

    Time frame: From Baseline to Week 12

  10. Change From Baseline in Serum Periostin Levels

    Time frame: From Baseline to Week 12

  11. Change From Baseline in Chemokine Ligand (CCL)-13 Levels

    Time frame: From Baseline to Week 12

  12. Change From Baseline in CCL-17 Levels

    Time frame: From Baseline to Week 12

  13. Change From Baseline in Lung Epithelial Cell Chloride Channel Accessory 1 (CLCA1) Gene Expression

    Time frame: From Baseline to Week 12

  14. Change From Baseline in Lung Epithelial Cell SerpinB2 Gene Expression at Week 12

    Time frame: From Baseline to Week 12

  15. Change From Baseline in Lung Epithelial Cell CCL-26 Gene Expression

    Time frame: From Baseline to Week 12

  16. Change From Baseline in Lung Epithelial Cell Nitric Oxide Synthase 2 (NOS2) Gene Expression

    Time frame: From Baseline to Week 12

  17. Change From Baseline in Lung Epithelial Cell Periostin (POSTN) Gene Expression

    Time frame: From Baseline to Week 12

  18. Relative Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO)

    Time frame: From Baseline to Week 12

  19. Relative Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)

    Time frame: From Baseline to Week 12

  20. Percentage of Participants With Treatment-Emergent Adverse Events

    Time frame: From Baseline to Week 20

  21. Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Lebrikizumab

    Time frame: Baseline up to Week 20 (assessed at Baseline, Weeks 8 and 20/dosing termination or early termination)

  22. Serum Lebrikizumab Concentration at Week 12

    Time frame: Predose (Hour 0) at Week 12

07

Study locations

28 sites
  • University of Arizona
    Tucson, Arizona 85724-5030, United States
  • LAC-USC Medical Center
    Los Angeles, California 90033, United States
  • University of California Davis Health System; Division of Pulmonary and Critical Care Medicine
    Sacramento, California 95817, United States
  • Yale School of Medicine
    New Haven, Connecticut 06510, United States
  • University of Miami School of Medicine - Sylvester at Deerfield
    Deerfield Beach, Florida Suite 200, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Iowa Hospitals & Clinics; Internal Medicine
    Iowa City, Iowa 52242, United States
  • Brigham and Women's Hospital; Pulmonary Division
    Boston, Massachusetts 02115, United States
  • Washington University; Pediatrics
    Saint Louis, Missouri 63110, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Wake Forest University Baptist Medical Center; Gastroenterology & Digestive Health
    Winston-Salem, North Carolina 27157-1045, United States
  • Pen Memory Center
    Philadelphia, Pennsylvania 19104, United States
  • Temple University Hospital ; Lung Center
    Philadelphia, Pennsylvania 19140, United States
  • University of Pittsburgh Medical Center Health System
    Pittsburgh, Pennsylvania 15213, United States
  • UTMB Pathology Clinical Services
    Galveston, Texas 77555-0743, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • University of Calgary
    Calgary, Alberta T2N 2T9, Canada
  • University of Alberta Hospital-SCC/WCM
    Edmonton, Alberta T6G 2S2, Canada
  • VGH Research Pavilion
    Vancouver, British Columbia V5Z 1L8, Canada
  • McMaster University Health Sciences Center
    Hamilton, Ontario L8N 3Z5, Canada
  • Hôpital Arnaud de Villeneuve
    Montpellier, 34295, France
  • Groupe Hospitalier Sud - Hôpital Haut Lévêque
    Pessac, 33600, France
  • Connolly Hospital
    Dublin, 15, Ireland
  • Skånes Universitetssjukhus, Lund
    Lund, 221 85, Sweden
  • Queen's University Belfast; NICRN Respiratory Research Office
    Belfast, BT9 7AB, United Kingdom
  • Glenfield Hospital
    Leicester, LE3 9QP, United Kingdom
  • St Mary's Hospital
    London, W2 1NY, United Kingdom
  • The Medicines Evaluation Unit
    Manchester, M23 9QZ, United Kingdom
08

References and documents

Publications

  • Austin CD, Gonzalez Edick M, Ferrando RE, Solon M, Baca M, Mesh K, Bradding P, Gauvreau GM, Sumino K, FitzGerald JM, Israel E, Bjermer L, Bourdin A, Arron JR, Choy DF, Olsson JK, Abreu F, Howard M, Wong K, Cai F, Peng K, Putnam WS, Holweg CTJ, Matthews JG, Kraft M, Woodruff PG; CLAVIER Investigators. A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER). Clin Exp Allergy. 2020 Dec;50(12):1342-1351. doi: 10.1111/cea.13731. Epub 2020 Oct 4. PubMed 32909660 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Oct 2016, 23 months.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 23 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2014
First posted
Mar 31, 2014
StartActual
Nov 6, 2014
Primary completionActual
Oct 13, 2016
CompletionActual
Oct 13, 2016
Last update
Sep 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02099656
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 31, 2014
Start date
Nov 6, 2014
Primary completion
Oct 13, 2016
Completion
Oct 13, 2016
Last update
Sep 6, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion